Mesa Laboratories Stock Probability Of Bankruptcy

MLAB Stock

USD 100.86 2.27 2.30%

Mesa Laboratories' odds of distress is under 30% at the present time. It has slight probability of undergoing some form of financial hardship in the near future. Chance of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Mesa balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Mesa Laboratories Piotroski F Score and Mesa Laboratories Altman Z Score analysis.

For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.

The current year's Market Cap is expected to grow to about 525.9 M. The current year's Enterprise Value is expected to grow to about 564.5 M

Mesa Laboratories Company chance of distress Analysis

Mesa Laboratories' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Mesa Laboratories Probability Of Bankruptcy

Less than 30%

Most of Mesa Laboratories' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mesa Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Mesa Laboratories probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Mesa Laboratories odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Mesa Laboratories financial health.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. If investors know Mesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesa Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

3.875

Dividend Share

0.64

Earnings Share

(45.62)

Revenue Per Share

42.3

Quarterly Revenue Growth

0.088

The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Accounts Payable	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Good Will	Current Deferred Revenue	Long Term Debt	Net Tangible Assets	Deferred Long Term Liab	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.9	0.48	-0.14	0.91	0.93	0.81	0.92	-0.1	0.75	0.93	0.76	0.97	0.87	0.92	0.72	0.76	0.91	0.27	-0.6	0.98	0.71	0.94
Total Stockholder Equity	0.9		0.13	0.26	0.67	0.67	0.81	0.72	0.03	0.6	0.72	0.53	0.84	0.6	0.66	0.73	0.52	0.65	-0.09	-0.52	0.89	0.72	0.77
Net Debt	0.48	0.13		-0.61	0.77	0.73	-0.01	0.71	-0.42	0.49	0.59	0.67	0.64	0.76	0.72	0.2	0.68	0.7	0.65	-0.36	0.42	-0.13	0.54
Retained Earnings	-0.14	0.26	-0.61		-0.42	-0.46	-0.07	-0.33	0.12	-0.19	-0.47	-0.35	-0.17	-0.55	-0.49	0.03	-0.45	-0.5	-0.93	0.0	-0.15	-0.07	-0.41
Net Receivables	0.91	0.67	0.77	-0.42		0.97	0.59	0.97	-0.2	0.69	0.94	0.86	0.95	0.96	0.96	0.59	0.83	0.96	0.54	-0.6	0.86	0.47	0.91
Total Liab	0.93	0.67	0.73	-0.46	0.97		0.67	0.95	-0.22	0.77	0.96	0.84	0.94	0.97	1.0	0.59	0.86	0.99	0.56	-0.59	0.89	0.57	0.94
Total Current Assets	0.81	0.81	-0.01	-0.07	0.59	0.67		0.63	0.15	0.59	0.78	0.52	0.65	0.59	0.69	0.65	0.5	0.71	0.18	-0.47	0.82	0.98	0.79
Accounts Payable	0.92	0.72	0.71	-0.33	0.97	0.95	0.63		-0.2	0.79	0.91	0.84	0.95	0.92	0.94	0.69	0.83	0.92	0.46	-0.65	0.87	0.5	0.89
Short Term Debt	-0.1	0.03	-0.42	0.12	-0.2	-0.22	0.15	-0.2		-0.07	-0.07	-0.4	-0.19	-0.22	-0.21	0.09	-0.29	-0.22	-0.17	0.61	0.0	0.22	-0.04
Intangible Assets	0.75	0.6	0.49	-0.19	0.69	0.77	0.59	0.79	-0.07		0.69	0.62	0.72	0.68	0.77	0.74	0.62	0.72	0.3	-0.48	0.72	0.5	0.68
Common Stock	0.93	0.72	0.59	-0.47	0.94	0.96	0.78	0.91	-0.07	0.69		0.77	0.91	0.96	0.97	0.63	0.82	0.97	0.55	-0.5	0.93	0.7	0.99
Property Plant Equipment	0.76	0.53	0.67	-0.35	0.86	0.84	0.52	0.84	-0.4	0.62	0.77		0.79	0.81	0.84	0.52	0.75	0.84	0.52	-0.81	0.64	0.39	0.71
Good Will	0.97	0.84	0.64	-0.17	0.95	0.94	0.65	0.95	-0.19	0.72	0.91	0.79		0.91	0.92	0.67	0.8	0.91	0.3	-0.59	0.94	0.53	0.91
Current Deferred Revenue	0.87	0.6	0.76	-0.55	0.96	0.97	0.59	0.92	-0.22	0.68	0.96	0.81	0.91		0.97	0.58	0.85	0.96	0.62	-0.49	0.86	0.5	0.94
Long Term Debt	0.92	0.66	0.72	-0.49	0.96	1.0	0.69	0.94	-0.21	0.77	0.97	0.84	0.92	0.97		0.59	0.84	1.0	0.59	-0.57	0.89	0.59	0.94
Net Tangible Assets	0.72	0.73	0.2	0.03	0.59	0.59	0.65	0.69	0.09	0.74	0.63	0.52	0.67	0.58	0.59		0.33	0.55	0.08	-0.43	0.72	0.57	0.66
Deferred Long Term Liab	0.76	0.52	0.68	-0.45	0.83	0.86	0.5	0.83	-0.29	0.62	0.82	0.75	0.8	0.85	0.84	0.33		0.84	0.55	-0.52	0.72	0.4	0.78
Long Term Debt Total	0.91	0.65	0.7	-0.5	0.96	0.99	0.71	0.92	-0.22	0.72	0.97	0.84	0.91	0.96	1.0	0.55	0.84		0.6	-0.58	0.88	0.61	0.95
Capital Surpluse	0.27	-0.09	0.65	-0.93	0.54	0.56	0.18	0.46	-0.17	0.3	0.55	0.52	0.3	0.62	0.59	0.08	0.55	0.6		-0.21	0.23	0.12	0.52
Short Long Term Debt	-0.6	-0.52	-0.36	0.0	-0.6	-0.59	-0.47	-0.65	0.61	-0.48	-0.5	-0.81	-0.59	-0.49	-0.57	-0.43	-0.52	-0.58	-0.21		-0.45	-0.35	-0.46
Net Invested Capital	0.98	0.89	0.42	-0.15	0.86	0.89	0.82	0.87	0.0	0.72	0.93	0.64	0.94	0.86	0.89	0.72	0.72	0.88	0.23	-0.45		0.75	0.94
Net Working Capital	0.71	0.72	-0.13	-0.07	0.47	0.57	0.98	0.5	0.22	0.5	0.7	0.39	0.53	0.5	0.59	0.57	0.4	0.61	0.12	-0.35	0.75		0.71
Capital Stock	0.94	0.77	0.54	-0.41	0.91	0.94	0.79	0.89	-0.04	0.68	0.99	0.71	0.91	0.94	0.94	0.66	0.78	0.95	0.52	-0.46	0.94	0.71

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	0.00321	0.005455	0.002645	0.001405	(0.57)	(0.54)
Asset Turnover	0.28	0.22	0.26	0.33	0.48	0.75
Net Debt	60.0M	(117.2M)	171.8M	137.4M	203.1M	213.2M
Total Current Liabilities	26.0M	32.6M	48.1M	43.4M	44.3M	46.5M
Non Current Liabilities Total	174.2M	162.7M	265.5M	225.0M	257.1M	269.9M
Total Assets	420.2M	600.2M	707.4M	661.8M	446.8M	469.1M
Total Current Assets	122.8M	303.0M	124.3M	119.0M	109.4M	114.8M
Total Cash From Operating Activities	26.6M	37.1M	39.2M	28.0M	44.1M	46.3M

	Return On Equity	-0.89
	Return On Asset	0.0169
	Profit Margin	(1.08) %
	Operating Margin	0.07 %
	Current Valuation	734 M
	Shares Outstanding	5.43 M
	Shares Owned By Insiders	5.78 %
	Shares Owned By Institutions	91.72 %
	Number Of Shares Shorted	150.21 K
	Price To Earning	433.94 X
	Price To Book	3.32 X
	Price To Sales	2.34 X
	Revenue	216.19 M
	Gross Profit	116.55 M
	EBITDA	(238.38 M)
	Net Income	(254.25 M)
	Cash And Equivalents	43.75 M
	Cash Per Share	8.23 X
	Total Debt	231.3 M
	Debt To Equity	0.57 %
	Current Ratio	2.90 X
	Book Value Per Share	29.79 X
	Cash Flow From Operations	44.13 M
	Short Ratio	5.19 X
	Earnings Per Share	(45.62) X
	Target Price	140.0
	Number Of Employees	736
	Beta	0.87
	Market Capitalization	535.48 M
	Total Asset	446.8 M
	Retained Earnings	(183.49 M)
	Working Capital	65.04 M
	Current Asset	10.74 M
	Current Liabilities	657 K
	Annual Yield	0.01 %
	Five Year Return	0.29 %
	Net Asset	446.8 M
	Last Dividend Paid	0.64

Mesa Laboratories Stock Probability Of Bankruptcy

Mesa Laboratories Company chance of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Mesa Laboratories Probability Of Bankruptcy

Mesa Probability Of Bankruptcy Driver Correlations

Mesa Probability Of Bankruptcy Peer Comparison

Mesa Laboratories Main Bankruptcy Drivers

Mesa Laboratories ESG Sustainability

Mesa Fundamentals

About Mesa Laboratories Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY